European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday

MT Newswires Live09-25 23:07

European equities traded in the US as American depositary receipts were moving lower late Wednesday morning, declining 0.27% to 1,442.84 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies argenx (ARGX) and Genfit (GNFT), which rose 4.3% and 3.6% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and internet advertising company Criteo (CRTO), which increased 2.9% and 2% respectively.

The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 6.3% and 3.2% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and software vendor SAP (SAP), which dropped 3% and 2.4% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Amarin (AMRN), which advanced 11% and 2% respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and mining company BHP Group (BHP), which were up 1.4% and 0.7% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and Trinity Biotech (TRIB) 5.7% and 4% respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and oil major BP (BP), which fell 2.8% and 2.5% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment